Related Experiment Video
Updated: Dec 13, 2025

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review
Nishant Jindal1, Aditya Jandial1, Arihant Jain1
1Department of Internal Medicine, 4th floor, Nehru Hospital, Post Graduate Institute of Medical Education and Research, Sector 12 Chandigarh (160012), India.
Abstract:
Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Clot Retraction and Fibrinolysis
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis I: Introduction
Types of Intermediate Filaments

